FREE PROMEGA WEBINAR
Date : 20th October 2022
Time : 11 am (Indonesia)
Promega Webinar, In this webinar we will discuss historically MSI has been used to screen for Lynch syndrome, a dominant hereditary cancer propensity. In 2015, MS1 status has been rediscovered as a biomarker for immunotherapeutic respose, making MST status an increasingly relevant tool for genetics and immuno-oncology applications. In this webinar, we will discuss MS testing gold standards and compare the different methods that are currently being used for MS testing for mismatch repair deficient (dMMR) tumors. We will also discuss the clinical relevance of the MSI-H biomarker focusing on the pathological and epidemiological characteristics of MSI-H/dMMR tumors, and the role of MSI testing in Lynch syndrome screening, colorectal cancer patient prognosis, and immunotherapy treatment.
In this webinar, you will learn about the:
• Comparison between technologies to measure MSI to current gold-standard methods
• Clinical utility of the MS biomarker for Lynch syndrome screening and immunotherapy treatment
• Current clinical practice guidelines for MSI testing
Link Webinar : https://bit.ly/3MIBLTR
